ENTER WEBSITE

Calgary Technologies Inc. rebrands to Platform Calgary

On March 4, 2019 Calgary Technologies Inc. will begin rebranding to Platform Calgary. As Platform Calgary, our focus will remain on supporting Calgary's innovation-driven companies by providing access to space, programming and advocacy, while also championing the vision for the new Platform Innovation Centre's design, activity, and culture. Our name change comes at the heels of our recent announcement as the new operator of the Platform Innovation Centre opening in East Village in the fall of 2020.

Why Platform Calgary?

There is a need to make innovation more accessible and visible to our community and this rebrand aligns with the City of Calgary's 10-Year Economic Strategy. Platform started with the idea of transforming Calgary into a global innovation hub. As Platform Calgary, we are turning that idea into action. Through this work the next wave of shared prosperity is being generated in our city, transforming local businesses into international success stories. By working together, we can make Calgary a global hub for startups and innovation.

It is about elevating innovation, and Platform Calgary is the next phase and evolution of Calgary Technologies Inc.

What's next?

March 4, 2019 marks our first official day of business as Platform Calgary. Over the next few months, you will see our materials transitioning over to our new name and brand. Our long-term priority is to put a focus on innovation in the heart of downtown Calgary. On March 4, 2019, we are opening Platform Beta at the Hillier Block in East Village. This historic 5,300-sq-ft building will serve as our interim downtown facility while the Platform Innovation Centre is being built.

We will continue to operate and provide services out of the Alastair Ross Technology Centre and The Inc.

Save the date for May 15, 2019: Annual Report to Community, Demo Day and Strategy Launch in the new Central Library. The event will showcase our Junction program graduates and will be the public launch event for our new Platform Calgary identity and strategic plan.

Have a question?

Contact us at communications@calgarytechnologies.com

ENTER WEBSITE

The following technologies have been assessed and reviewed by our expert team and are currently available for licensing or sponsored research.

Best practice programs to support early-phase startups from idea to revenue.

  • Programs / Workshops
    • Junction 31

      Junction 31

      Applications for Cohort 3 now open

      A pre-seed program that helps build a strong foundation for innovation-driven entrepreneurs.

       

      Learn more Apply
    • Discover

      Discover

      Registration for spring 2019 now open

      Understanding customer behaviour is essential to your startup success. This applied program teaches how to engage customers and discover their motivations, preferences and needs. 

      Learn more Register
    • 321 Growth Academy: Sales 101

      321 Growth Academy: Sales 101

      Registration now open!

      A full-day crash-course in B2B sales for business and technical founders and execs.

      Learn more Register
    • 321 Growth Academy: Lean Sales

      321 Growth Academy: Lean Sales

      Registration now open!

      This program includes eight half day sessions plus a one-on-one coaching session.  

      Learn more Register
    • 321 Growth Academy: Marketing 101

      321 Growth Academy: Marketing 101

      Registration now open!

      Marketing 101 is a full-day crash course in B2B marketing for business and technical founders. You’ll learn how to create an effective marketing capacity in your company, assess where you’re at, and develop an action plan to get you from here to there.

      Learn More Register
    • 321 Growth Academy: Growth Marketing

      321 Growth Academy: Growth Marketing

      Registration now open!

      An eight-week course for Startup Founders, Executives and Marketing Leaders to take a “learning by doing” approach to marketing impact. It’s all about assessing your market and current marketing, learning new marketing ideas and approaches and putting them into action by working on real-world marketing challenges facing your company. The outcome? A more focused and impactful return on your marketing investment and marketing that drives revenue for your business.

      Learn More Register
    • 321 Growth Academy: People 101

      321 Growth Academy: People 101

      Registration now closed

      A full-day crash course in human resources (HR) for business and technical founders and leaders. You’ll learn how to build an effective people capacity in your company, how to assess where you’re at with your HR function and how to develop an action plan so you can attract and develop the culture and team you need to grow.

      Learn More
    • 321 Growth Academy: Agile HR

      321 Growth Academy: Agile HR

      Registration now open!

      Agile HR is an 8-session program for startup founders, executives and people/HR leaders to take an agile and “learning by doing” approach to the People/HR function. 

      Learn More Register

    Programs / Workshops

  • Accelerator Programs
    • TELUS Accelerator & Incubator Programs

      TELUS Accelerator & Incubator Programs

      CTI and TELUS partner to support Canadian technology startups at all stages of growth. At the early stage, the TELUS Technology Incubator (TTI) helps startups develop a robust go to market strategy. For growth stage startups, the TELUS Technology Accelerator (TTA) offers a combination of advisory services that strengthen all aspects of their business, leading to increased growth, higher visibility with potential customers and investors, and potential enterprise opportunities with TELUS.

      Learn more

    Accelerator Programs

  • Services
    • CEO Roundtable

      CEO Roundtable

      A monthly peer advisory forum for CEOs, board members and founders of technology companies to openly discuss their challenges in a confidential, safe environment. The goal of the roundtables are to provide "just-in-time" advice on current issues, enhance accountability and accelerate actions/decisions. 

      "This roundtable has transformed our company, period. There are not enough good things I can say about this group. Even banks recognize its significance toward the foundation for a strong company." - Jeremy Bridge

      Learn more Apply
    • Venture Mentoring Service of Alberta (VMSA)

      Venture Mentoring Service of Alberta (VMSA)

      The Venture Mentoring Service of Alberta (VMSA) is a volunteer organization that provides objective, conflict-free guidance to entrepreneurs in southern Alberta. Each entrepreneur is matched with a team of mentors, which gives a more in-depth experience than traditional one-on-one relationships.

      Learn more
    • Startup Visa

      Startup Visa

      Canada's Startup Visa (SUV) Program is intended to attract foreign entrepreneurs who wish to establish new, high-growth businesses in Canada that will support innovation and job creation. 

      Learn More Apply
    • Global Opportunities in Calgary

      Global Opportunities in Calgary

      As a champion of the innovation ecosystem, CTI and our partners are helping to drive change and establish Calgary as a global hub. Explore some of our global opportunities in Calgary.

      Learn More
    • Funding Support

      Funding Support

      Prepare your approach to venture financing through performing a "12 Point Business Assessment".

      Having a plan to fund your business from many sources, which may include equity investors, is just as important as your business plan.

      Apply
    • Intellectual Property

      Intellectual Property

      Questions about intellectual property? Want to learn more? Connect with our partners at Innovate Calgary. 

      Learn more

    Services

Stay Up-To-Date

Join our mailing list

Parvus Therapeutics Announces Exclusive Worldwide Licence with Novartis

Wednesday, April 19, 2017

Innovate Calgary would like to congratulate Parvus Therapeutics Inc. on obtaining an exclusive licence and collaboration agreement with Novartis to advance the treatment of type 1 diabetes. 

 

Parvus Therapeutics Announces Exclusive Worldwide License and Collaboration Agreement for the Development and Commercialization of Its Lead Nanomedicine to Treat Type 1 Diabetes

CALGARY, Alberta — April 19, 2017 — Parvus Therapeutics, a biopharmaceutical company developing disease-modifying nanomedicines to halt or reverse autoimmune disease without causing general immune suppression, has entered into a license and collaboration agreement with Novartis for its lead Navacim for treating type 1 diabetes. Navacims constitute a novel pharmacological class of therapeutic comprised of nanoparticles (NPs) coated with disease-relevant peptide-major histocompatibility complexes (pMHCs) that alter the behavior of disease-causing T lymphocytes. Navacims are the first biopharmaceuticals to demonstrate in preclinical models the ability to restore immune tolerance in a disease-specific manner through in vivo formation and expansion of regulatory T-cells (T-regs) without causing general immune suppression.

Under the terms of the agreement, Novartis receives exclusive, worldwide rights to use Parvus’ Navacim technology to develop and commercialize products for the treatment of type 1 diabetes (T1D) and will be responsible for clinical-stage development and commercialization activities. Parvus will be primarily responsible for conducting the ongoing preclinical work for the T1D program and filing the IND in collaboration with Novartis through a joint steering committee. Parvus has received an upfront payment and will receive research funding to support preclinical activities. In addition, Parvus is eligible to receive downstream development, regulatory, and sales milestone payments, as well as product royalties. Novartis has also made an equity investment in Parvus.

T1D Navacims are composed of an iron oxide nanoparticle conjugated with multiple copies of a peptide derived from a pancreatic autoantigen, presented in the context of an MHC molecule. Preclinical studies have shown that Navacims achieve their therapeutic effect by reprogramming cognate pathogenic T cells into tissue-specific beneficial T-regs and thereafter inducing their systemic expansion. The expanded T-regs target and suppress the autoimmune disease-causing immune cells, sparing other immune cells and restoring the immune system to the normal steady state. Navacims have the potential, therefore, to specifically treat the autoimmune disease without increasing the risk of infection.

“This is a transformative collaboration for Parvus. We are excited by this strong endorsement of the science behind our Navacim platform, as well as the opportunity to collaborate closely with a globally recognized leader in the field of immunology and autoimmune disease,” stated Janice M. LeCocq, CEO of Parvus. "This will augment our resources across the Navacim platform and accelerate the development of our T1D program. We are also pursuing the development of multiple Navacims that target autoimmune diseases where there is high unmet need for disease-modifying drugs without causing systemic immunosuppression.”

About T1D
Type 1 diabetes (T1D) is caused by a chronic, progressive autoimmune response against the insulin-producing beta cells of the pancreas that ultimately leads to insulin-deficiency and high blood glucose levels. As a result, patients with T1D require insulin replacement therapy, usually involving multiple injections of insulin on a daily basis. Unfortunately, insulin is not a cure and does not treat the underlying cause of T1D. In addition, insulin replacement therapy cannot mimic the exquisitely tight control of glucose levels achieved by endogenous insulin production and, with time, can lead to serious complications, including blindness, stroke, myocardial failure, amputation and peripheral neuropathy. Currently, as many as 1.25 million Americans have T1D and the incidence of disease is steadily increasing. T1D is typically first diagnosed in children and young adults.

About Parvus Therapeutics Inc.
Parvus Therapeutics Inc. is a privately-held biopharmaceutical company engaged in the development and commercialization of Navacim therapeutics, novel nanoparticle based immune complexes that induce the in vivo expansion of specific regulatory cells resulting in the restoration of immune homeostasis. Navacims can be readily tailored to target a broad range of autoimmune diseases and have the potential to radically improve the lives of patients suffering from these diseases. Navacims were discovered by Pere Santamaria, M.D., Ph.D. Chief Scientific Officer and Founder of Parvus, and Julia McFarlane, Diabetes Research Professor of the Cumming School of Medicine at the University of Calgary and Group Leader at Institut D’Investigacions Biomediques August Pi i Sunyer.

Media Inquiries:
Justin Jackson
212-213-0006, ext. 327
jjackson@burnsmc.com

Stakeholders & Partners

Loading...